We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Opdivo Gets Breakthrough Designation for Another Cancer Treatment
Opdivo Gets Breakthrough Designation for Another Cancer Treatment
The FDA awarded Bristol-Myers Squibb’s Opdivo a breakthrough therapy designation for metastatic renal cell carcinoma, adding another potential indication to the growing list for the PD-1 inhibitor.